AT-001 is an oral treatment being designed to treat rare and common forms of dementia by preventing and dissolving amyloid plaques and tau tangles. This is achieved by destabilizing the inter/intra-molecular interactions that form and maintain these detrimental aggregates.

AT-004 is a topical cream being engineered to treat inflammatory skin diseases, such as acne vulgaris, atopic dermatitis, rosacea, and psoriasis. AT-004 targets the non-neuronal cholinergic system, where cholinergic action has been shown to exhibit significant anti-inflammatory and repair activities in the skin.

AT-002 is a peptide mimetic of the KIR domain of SOCS1 – a potent JAK-STAT pathway inhibitor – for the treatment of autoimmune uveitis and other autoimmune/inflammatory diseases, such as lupus, psoriasis, juvenile dermatomyositis, and cytokine storm syndromes arising from CAR-T immunotherapy or COVID infection.

AT-003 is small-molecule mitophagy and autophagy modulator that aims to counteract the consequences of aberrant CLEC16A activity, which has been strongly linked to 16 autoimmune diseases – including lupus, rheumatoid arthritis, multiple sclerosis, and type 1 diabetes, as well as Parkinson’s disease.

AT-005 is a novel therapeutic approach to prevent severe asthma attacks by targeting the C strain of Rhinovirus (RV-C), which is the most common trigger of these exacerbations in allergic asthma, by blocking interactions of RV-C with its entry receptor, CDHR3.